Expression of the Innate Immune Receptor LILRB5 on Monocytes is Associated with Mycobacteria Exposure
Authors
Affiliations
Antigen presenting cells (APC) are critical components of innate immunity and consequently shape the adaptive response. Leukocyte Ig Like Receptors (LILR) are innate immune receptors predominantly expressed on myeloid cells. LILR can influence the antigen presenting phenotype of monocytic cells to determine the nature of T cell responses in infections including Mycobaterium leprae. We therefore investigated the relevance of LILR in the context of Mycobacterium tuberculosis. Real-time PCR studies indicated that the transcriptional profile of the orphan receptor LILRB5 was significantly up-regulated following exposure to mycobacteria. Furthermore, LILRA1 and LILRB5 were able to trigger signalling through direct engagement of mycobacteria using tranfectant cells incorporating a reporter system. We describe for the first time the expression of this receptor on T cells, and highlight the potential relevance to mycobacterial recognition. Furthermore, we demonstrate that crosslinking of this receptor on T cells increases proliferation of cytotoxic, but not helper, T cells.
Merzah M, Poliska S, Balogh L, Sandor J, Fiatal S Curr Issues Mol Biol. 2024; 46(12):13893-13902.
PMID: 39727958 PMC: 11727024. DOI: 10.3390/cimb46120830.
Human leukocyte immunoglobulin-like receptors in health and disease.
Redondo-Garcia S, Barritt C, Papagregoriou C, Yeboah M, Frendeus B, Cragg M Front Immunol. 2023; 14:1282874.
PMID: 38022598 PMC: 10679719. DOI: 10.3389/fimmu.2023.1282874.
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.
Ridgley L, Caron J, Dalgleish A, Bodman-Smith M Front Immunol. 2023; 13:1065495.
PMID: 36713444 PMC: 9880221. DOI: 10.3389/fimmu.2022.1065495.
LILRB4, an immune checkpoint on myeloid cells.
Yang T, Qian Y, Liang X, Wu J, Zou M, Deng M Blood Sci. 2022; 4(2):49-56.
PMID: 35957669 PMC: 9362873. DOI: 10.1097/BS9.0000000000000109.
Fan J, Wang L, Chen M, Zhang J, Li J, Song F World J Surg Oncol. 2022; 20(1):92.
PMID: 35321724 PMC: 8943947. DOI: 10.1186/s12957-022-02562-w.